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Abstract
Introduction Hospital-acquired pneumonia (HAP) due to
Pseudomonas aeruginosa is associated with high mortality
rates. The metallo-β-lactamases (MBLs) are emerging enzymes
that hydrolyze virtually all β-lactams. We aimed to assess P.
aeruginosa  HAP mortality in a setting of high-rate MBL
production
Methods A prospective cohort study was performed at two
tertiary-care teaching hospitals. A logistic regression model was
constructed to identify risk factors for 30-day mortality.
Results One-hundred and fifty patients with P. aeruginosa HAP
were evaluated. The 30-day mortality was 37.3% (56 of 150):
57.1% (24 of 42) and 29.6% (32 of 108) for patients with HAP
by MBL-producing P. aeruginosa and by non-MBL-producing P.
aeruginosa, respectively (relative risk, 1.93; 95% confidence
interval (CI), 1.30–2.85). The logistic regression model
identified a higher Charlson comorbidity score (odds ratio, 1.21;
95% CI, 1.04–1.41), presentation with severe sepsis or septic
shock (odds ratio, 3.17; 95% CI, 1.30–7.72), ventilator-
associated pneumonia (odds ratio, 2.92; 95% CI, 1.18–7.21),
and appropriate therapy (odds ratio, 0.24; 95% CI, 0.10–0.61)
as independent factors for 30-day mortality. MBL production
was not statistically significant in the final model.
Conclusion MBL-producing P. aeruginosa HAP resulted in
higher mortality rates, particularly in patients with ventilator-
associated pneumonia, most probably related to the less
frequent institution of appropriate antimicrobial therapy.
Therapeutic approaches should be reviewed at institutions with
a high prevalence of MBL.
Introduction
Hospital-acquired pneumonia (HAP), particularly ventilator-
associated pneumonia (VAP), causes considerable morbidity
and mortality despite antimicrobial therapy and advances in
supportive care [1,2]. It is the second most frequent nosoco-
mial infection and is the major cause of death among hospital-
acquired infections [1]. Pseudomonas aeruginosa is a leading
cause of nosocomial infections all over the world, especially of
HAP and VAP, when it usually ranks as the first or second
causative pathogen [1-3]. This organism is uniquely problem-
atic because of a combination of inherent resistance to many
drug classes and its ability to acquire resistance to all relevant
treatments [3]. Severe infections due to P. aeruginosa are
associated with high mortality regardless of appropriate anti-
microbial therapy [3].
The metallo-β-lactamases (MBLs) have recently emerged as
one of the most worrisome resistance mechanisms owing to
their capacity to hydrolyze, with the exception of aztreonam, all
β-lactam agents, including the carbapenems; and also
because their genes are carried on highly mobile elements,
allowing easy dissemination of such genes among Gram-neg-
CI = confidence interval; HAP = hospital-acquired pneumonia; MBL = metallo-β-lactamase; MBL-PA = metallo-β-lactamase-producing Pseudomonas 
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ative rods [4]. MBLs have been rapidly spreading through
many countries, particularly from Southeast Asia, Europe, and
Latin America [4-6]. The emergence of these enzymes drasti-
cally compromises effective treatments of nosocomial infec-
tions by this organism, bringing us closer to the much feared
'end of antibiotics' [4-6].
We have recently demonstrated that nosocomial infections
due to metallo-β-lactamase-producing P. aeruginosa (MBL-
PA) isolates have been associated with higher mortality rates
[7]. In the present article, we aimed to assess the mortality of
the subset of patients with HAP due to P. aeruginosa in a set-
ting of high-rate MBL production.
Materials and methods
Study design and patients
A contemporary cohort study of consecutive patients with P.
aeruginosa nosocomial infections was performed at two terti-
ary-care teaching hospitals in Porto Alegre, southern Brazil.
The study period was from September 2004 to June 2005 at
São Lucas Hospital, a 600-bed hospital, and from January to
June 2005 at Hospital de Clínicas de Porto Alegre, a 1,200-
bed hospital [7].
In the current study, we analyzed patients ≥ 18 years, who did
not have cystic fibrosis, who had been diagnosed with HAP
defined as follows. First, the presence of positive cultures for
P. aeruginosa either recovered from respiratory secretions
(>106 cfu/ml from endotracheal aspirates or >104 cfu/ml from
bronchoalveolar lavage) after 48 hours of hospital admission,
or within 48 hours if the patient had been hospitalized in the
past 60 days, or recovered from blood without the presence
of any other pathogen in respiratory secretions. Second, the
presence of a radiographic infiltrate that was new or progres-
sive, along with the presence of two or more of the following
criteria: fever (temperature >38°C) or hypothermia (tempera-
ture <36°C), purulent sputum, leukocytosis (>10,000 cells/
mm3) or leukopenia (<4,000 cells/mm3), and a decline in oxy-
genation. Sputum was considered purulent if >25 neu-
trophiles and <10 epithelial cells per high power field were
present. VAP was defined as HAP that developed after 48
hours of mechanical ventilation.
Patients were excluded if they did not fulfill these criteria for
HAP. Patients were followed from the first isolation of P. aeru-
ginosa to discharge from hospital or to death. Antimicrobial
agents used were at the discretion of the patient's physicians,
not the investigators. The ethics review boards of both hospi-
tals approved the study.
Data collection
Data were collected from medical charts and/or hospital com-
puter system databases, both during and after the patients'
hospitalization. The researchers were blinded for the MBL sta-
tus of P. aeruginosa isolates during data collection.
Microbiology
Conventional microbiology methods were used for P. aerugi-
nosa identification, and susceptibility tests were performed by
disk-diffusion methods according to Clinical and Laboratory
Standards Institute, (formerly National Committee for Clinical
Laboratory Standards), guidelines [8]. Susceptibility was
tested for amikacin, aztreonam, cefepime, ceftazidime, cipro-
floxacin, imipenem, meropenem, piperacillin-tazobactam, and
polymyxin B. Susceptibility of the latter was determined using
the interpretative criteria (≥ 14 mm) proposed elsewhere [9].
All isolates resistant to ceftazidime were screened for MBL
production with ceftazidime in the presence of 3 µl 2-mercap-
topropionic acid as previously described [10].
Variables and definitions
The main outcome was 30-day mortality. Other secondary out-
comes were the length of need for vasoactive drugs and the
length of mechanical ventilation (both were assessed in
survivors).
The variable in the study was MBL production. Other inde-
pendent variables analyzed included the following: age; sex;
Charlson comorbidity score [11] (assessed at the moment of
HAP diagnosis); baseline diseases; iatrogenic immunosup-
pression, such as chemotherapy-induced neutropenia (neu-
trophile count ≤ 1,000 mm3), and/or receipt of corticoid drugs
(prednisone ≥ 10 mg daily or equivalent doses) or other immu-
nosuppressive agents for >14 days; the presence of other
concomitant infections (infections by other organisms at a site
other than the lung, excluding coagulase-negative staphyloco-
cci in a single blood culture); a previous surgical procedure
during the hospital stay; the length of hospital stay (before the
diagnosis of HAP); presentation of HAP with severe sepsis or
septic shock [12]; infection by P. aeruginosa at more than one
site (not including patients with HAP and bacteremia); pol-
ymicrobial infection (isolation of another organism from the
respiratory secretions at the moment of P. aeruginosa HAP
diagnosis); associated bacteremia (isolation of P. aeruginosa
from one or more blood samples); VAP; receiving appropriate
empirical therapy (defined as the administration of an antimi-
crobial agent to which the isolate was susceptible in vitro in ≤
24 hours of sample collection); receiving appropriate definitive
therapy (defined as the use for at least 48 hours of an antimi-
crobial agent to which the isolate was susceptible in vitro);
time to receiving appropriate definitive therapy (only for those
who have not received appropriate empirical therapy; time in
days from the sample collection to the first dose of appropriate
therapy); and combination antibiotic treatment (treatment with
more that one agent with in vitro susceptibility).
Aminoglycosides in monotherapy were not considered appro-
priate treatment therapy despite in vitro susceptibility [3].Available online http://ccforum.com/content/10/4/R114
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Statistical analysis
All statistical analyses were carried out using SPSS for Win-
dows, version 13.0. The relative risk (RR) and the 95% confi-
dence interval (CI) were calculated for 30-day mortality of
patients with MBL-PA HAP and of patients with non-MBL-PA
HAP. P values were calculated using the chi-squared test or
Fischer exact test for categorical variables, and using Stu-
dent's t  test or the Wilcoxon rank-sum test for continuous
variables.
A logistic regression model was constructed to identify inde-
pendent factors associated with 30-day mortality using a for-
ward stepwise approach. Variables for which the P value was
< 0.20 in univariate analysis were included in the model. P =
0.05 was set as the limit for acceptance or removal of the
terms in the model. MBL production remained in the model
independent of the P value. All tests were two-tailed and P ≤
0.05 was considered significant.
Results
Patients and mortality
A total of 473 patients presented the isolation of P. aeruginosa
after >48 hours of hospital admission. Of these, 171 pre-
sented the isolation of P. aeruginosa in respiratory secretions.
Twenty-one patients were excluded because they did not fulfill
Table 1
Characteristics of patients according to 30-day mortality
30-day mortality
Variable Yes (n = 56) No (n = 94) P
Age (years) 66.4 ± 18.4 60.4 ± 17.9 0.38
Sex (male) 42 (75.0) 63 (67.0) 0.40
Charlson score 4 (2–6) 3 (2–6) 0.15
Comorbidities
Neurological 14 (48.3) 44 (36.4) 0.33
Cardiac 20 (69.0) 69 (57.0) 0.33
Pulmonary 12 (41.4) 55 (45.5) 0.85
Malignancy 6 (20.7) 21 (17.4) 0.88
Diabetes 10 (34.5) 29 (24.0) 0.36
Renal 4 (13.8) 28 (23.1) 0.20
Cirrhosis 4 (13.8) 12 (9.9) 0.37
AIDS 2 (6.9) 8 (6.6) 0.61
Immunosuppression 23 (41.1) 33 (35.5) 0.58
Other infections 17 (30.4) 25 (26.6) 0.76
Previous surgery 24 (42.9) 38 (40.4) 0.90
Length of hospital stay (days) 16.5 (7.5–30) 15.5 (5–30) 0.52
Severe sepsis or septic shock 40 (71.4) 31 (33.0) <0.001
Ventilator-associated pneumonia 33 (58.9) 22 (23.4) <0.001
>1 site 7 (12.5) 15 (16.0) 0.73
Polymicrobial pneumonia 23 (41.1) 30 (31.9) 0.38
Bacteremia 12 (21.4) 9 (9.6) <0.05
Appropriate therapy
At any moment 31 (55.5) 78 (83.0) <0.001
≤ 24 hours 11 (19.6) 35 (37.2) <0.05
Time to initiate appropriate therapy (days) 4.5 ± 2.1 5.1 ± 5.1 0.60
Combination therapy (n = 109) 3 (9.7) 15 (19.9) 0.18
Data presented as the mean ± standard deviation, as the median (interquartile range), or as n (%).Critical Care    Vol 10 No 4    Zavascki et al.
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the criteria for HAP. A total of 150 patients were analyzed.
Forty-two (28.0%) patients presented MBL-PA HAP.
The 30-day mortality was 37.3% (56 of 150) and represented
76.7% of the 73 deaths. Among patients with MBL-PA HAP
the 30-day mortality was 57.1% (24 of 42), compared with
29.6% (32 of 108) for non-MBL-PA patients (RR, 1.93; 95%
CI, 1.30–2.85; P < 0.01). The overall mortality rate was 18.7
per 1,000 patient-days: 26.5 per 1,000 patient-days among
MBL-PA-infected patients and 15.8 per 1,000 patient-days
among non-MBL-PA-infected patients (P = 0.02). The median
length of follow-up was 19 days (interquartile range, 9–31
days): 16 days (interquartile range, 7–28 days) for those
patients with MBL-PA HAP and 19.5 days (interquartile range,
10–31.5 days) for those patients with non-MBL-PA HAP (P =
0.19). The median length of follow-up of those patients who
did not die within 30 days did not differ between patients with
MBL-PA HAP and patients with non-MBL-PA HAP (29.5 days
(interquartile range, 22–71 days) versus 24.5 days (interquar-
tile range, 14–39.5 days), respectively; P = 0.22).
Fifty-five patients (36.7%) had VAP. Patients with VAP had a
30-day mortality of 60.0% (33 of 55): 77.3% (17 of 22) for
patients with MBL-PA VAP compared with 48.5% (16 of 33)
for those patients with non-MBL-PA VAP (RR, 1.59; 95% CI,
1.05–2.42; P = 0.03).
Risk factors for mortality
The characteristics of patients according to 30-day mortality
are presented in Table 1. Factors associated with mortality
within 30 days in the univariate analysis were severe sepsis or
septic shock, VAP, and bacteremia. Comorbidity scores were
higher in patients who died within 30 days, but there was no
statistically significant difference. Both empirically appropriate
therapy and receiving appropriate therapy at any moment were
significant protective factors for 30-day mortality; however, a
greater effect was observed for therapy at any time.
Considering only patients who received appropriate therapy (n
= 109), there was no statistically significant difference in mor-
tality rates according to the time to administration of appropri-
ate therapy. The 30-day mortality rates were 21.7% (≤ 24
hours), 32.0% (>24 hours but ≤ 72 hours), and 34.2% (>72
hours) (P = 0.41).
Multivariate analysis
The results of multivariate analysis are presented in Table 2.
The Charlson score, severe sepsis or septic shock, VAP, and
appropriate treatment at any moment were significantly asso-
Table 2
Multivariate analysis of factors associated with 30-day mortality Only variables of the final model are presented.
30-day mortality
Variable Odds ratio (95% confidence interval) P
Metallo-β-lactamase 1.77 (0.72–4.36) 0.21
Charlson 1.21 (1.04–1.41) 0.02
Severe sepsis or septic shock 3.17 (1.30–7.72) 0.01
Ventilator-associated pneumonia 2.92 (1.18–7.21) 0.02
Appropriate antimicrobial therapy 0.24 (0.10–0.61) <0.01
Table 3
Antibiotic resistance profiles of 42 metallo-β-lactamase-producing Pseudomonas aeruginosa
Profile Antibiotic n %
Polymyxin B Aztreonam Piperacillin-
tazobactam
Amikacin Ciprofloxacin Ceftazidime Cefepime
1 Susceptible Susceptible Resistant Resistant Resistant Resistant Resistant 17 40.5
2 Susceptible Resistant Resistant Resistant Resistant Resistant Resistant 14 33.3
3 Susceptible Susceptible Resistant Susceptible Resistant Resistant Resistant 6 14.8
4 Susceptible Susceptible Susceptible Resistant Resistant Resistant Resistant 2 4.8
5 Susceptible Resistant Susceptible Resistant Resistant Resistant Resistant 2 4.8
6 Susceptible Resistant Resistant Resistant Susceptible Resistant Resistant 1 2.4Available online http://ccforum.com/content/10/4/R114
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ciated with 30-day mortality. Bacteremia and antimicrobial
combination were not statistically significant and were
excluded from the model. MBL production was not signifi-
cantly associated with the outcome in the final model, but was
statistically significant in the multivariate model (RR, 2.84;
95% CI, 1.24–6.52, P = 0.01) before the inclusion of appro-
priate antimicrobial therapy in the model. Specific comorbidi-
ties such as cirrhosis and AIDS were not included in the model
because they were significantly associated with higher Charl-
son scores (data not shown).
Secondary outcomes
Among the 77 survivors, patients with MBL-PA HAP pre-
sented significantly longer length of need for vasoactive drug
therapy than non-MBL-PA patients (mean, 17.5 ± 3.5 days
versus 3.6 ± 3.3 days; P < 0.001). The length of mechanical
ventilation was also longer for patients with MBL-PA HAP than
for non-MBL-PA patients, although without statistical signifi-
cance (mean, 13.0 ± 9.0 days versus 7.8 ± 4.9 days; P =
0.12).
Resistance patterns
A total of 38 distinct antibiotic resistance profiles were
observed in P. aeruginosa isolates, but only six distinct pat-
terns were observed among MBL-PA isolates. These latter
profiles are presented in Table 3. Among non-MBL-PA iso-
lates, 36 resistance profiles were found. The commonest pro-
file was susceptibility to all tested drugs (27 patients, 25.0%),
followed by susceptibility to all drugs except aztreonam (14
patients, 13.0%), and susceptibility to ceftazidime and pipera-
cillin-tazobactam and resistance to the other drugs (10
patients, 9.3%). Other profiles each accounted for 6.5% or
less of the total.
MBL-producing P. aeruginosa HAP
Among the 42 patients with MBL-PA HAP, 41 received antimi-
crobial therapy and one did not receive any antibiotic. This lat-
ter patient had a missed diagnosis of HAP and died after four
days of the onset of infection. Twenty-one (51.2%) of the 41
treated patients received appropriate therapy: 10 patients
(47.6%) received such therapy in ≤ 72 hours, and three
patients (14.3%) received appropriate antibiotic in ≤ 24 hours.
Patients who received any therapy in ≤ 72 hours (n = 10)
tended to present a lower 30-day mortality than those who
Table 4
Therapy and mortality of patients with Pseudomonas aeruginosa producing metallo-β-lactamase hospital-acquired pneumonia
Treatment Hospital-acquired pneumonia (n = 42) Ventilator-associated pneumonia (n = 22)
Treated patients 30-day mortality (n = 24) Treated patients 30-day mortality (n = 17)




Appropriate combination therapy 3 (7.1) 0 (0.0) 1 (4.5) 0 (0.0)
Polymyxin B + aztreonam 2 0 1 0
Aztreonam + amikacin 1 0 - -
Nonappropriate combination therapy 3 (7.1) 2 (66.7) 1 (4.5) 0
Aztreonam + ceftazidime + 
amikacin
11- -
Imipenem + ceftazidime 1 0 1 0
Imipenem + ciprofloxacin 1 1 - -
Nonappropriate monotherapy 17 (40.5) 12 (70.6) 8 (36.4) 8 (100)
Cefepime 7 5 3 3
Meropenem 6 3 2 2
Imipenem 2 2 2 2
Ceftazidime 1 1 1 1
Amikacin 1 1 - -
Without therapy 1 (2.4) 1 (100) - -
aThe association of in vitro nonsusceptible antibiotics were used in three patients: ceftazidime (one patient), cefepime (one patient), and 
ceftazidime + amikacin (one patient); all were survivors. bOne patient received the association of cefepime (in vitro nonsusceptible); survivor. cOne 
patient received the association of ciprofloxacin (in vitro nonsusceptible); nonsurvivor.Critical Care    Vol 10 No 4    Zavascki et al.
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received therapy after 72 hours (n = 31): 30.0% and 64.5%,
respectively (RR, 0.45; 95% CI, 0.17–1.24; P = 0.06). Antimi-
crobial therapies of patients with MBL-PA HAP are presented
in Table 4.
Considering only those 21 patients who received appropriate
therapy, there was no statistically significant difference in mor-
tality between receiving therapy in ≤ 72 hours (n = 9) and in
>72 hours (n = 12) for 30-day mortality (33.3% versus 50.0%;
RR, 0.67; 95% CI, 0.23–1.97; P  = 0.38). Among these
patients, no specific antibiotic agent was associated with
lower mortality (P = 0.54).
Discussion
MBL production is an emerging resistance mechanism in
Gram-negative rods, particularly in P. aeruginosa [5,6]. In a
recent article we showed that nosocomial infections due to
MBL-PA were associated with increased mortality when com-
pared with those infections caused by non-MBL-PA isolates,
confirming that such a resistance mechanism is actually a clin-
ical threat [7]. In this latter study, all sites of nosocomial infec-
tions were analyzed together but no data were available
regarding clinical outcomes of more severe infections, such as
HAP. The current study was carried out in order to reappraise
the mortality of HAP, which is usually associated with high
mortality rates, especially among critically ill patients [1,2], in a
setting of high prevalence of MBL production. To the best of
our knowledge, this was the first study to assess the impact of
this emerging resistance mechanism on the outcome of
patients with HAP.
Our study showed a high mortality in patients with HAP by P.
aeruginosa, and MBL production by these isolates signifi-
cantly increased the mortality of these patients. This effect was
probably mediated by a more frequent inappropriateness of
antimicrobial therapy for MBL-PA infections, considering that
MBL production was not significantly associated with 30-day
mortality when the variable administration of appropriate ther-
apy was included in the multivariate analysis.
Both presentation with severe sepsis or septic shock and VAP
had the strongest impact on 30-day mortality, supporting the
importance of these factors in overall mortality as recognized
in many studies [13-15]. Higher comorbidity scores had also
a significant impact on the outcome of patients.
Our study did not demonstrate a significant effect of early
appropriate therapy on mortality. Actually, a significant effect
was not shown even adjusting for the comorbidity score, pres-
entation of severe sepsis or septic shock, and VAP in patients
who had received appropriate therapy (data not shown). This
might be caused by the fact that most of patients who received
appropriate therapy (66.1%, 72 of 109) received it in <72
hours; it may therefore be possible that our sample size lacks
sufficient power to detect differences within this period of
time. Nevertheless, crude analysis of mortality among patients
who received appropriate therapy showed, although without
statistical significance, lower mortality rates for those who
started treatment earlier, particularly within 72 hours. Since
early therapy is recognizably associated with better outcomes
[2,14,15], we emphasize its importance and attribute, at least
partially, the lack of statistical significance in our multivariate
model to the reason exposed earlier.
Few antibiotic resistance profiles were observed among MBL-
PA HAP patients. Four isolates were unexpectedly susceptible
to piperacillin-tazobactam. Such an interesting finding, how-
ever, has already been reported previously [16,17]. MBLs
have been a major determinant of carbapenem resistance at
our institutions [18]. However, other resistance mechanisms
to these agents were also present in some isolates, such as
the loss of OprD outer membrane protein in the case of imi-
penem, and this latter mechanism with an associated overex-
pression of the MexAB-OprM efflux pump, as is the case for
meropenem [18,19].
Worrisome high mortality rates were observed among patients
with MBL-PA HAP despite appropriate therapy, particularly
among those with VAP. Although no specific antibiotic proved
to be significantly associated with lower mortality, aztreonam
in monotherapy presented the lowest mortality among appro-
priate treatments for MBL-PA HAP (two of eight patients,
25.0%). All patients with VAP who were treated with this anti-
biotic in monotherapy died during their hospitalization, how-
ever (data not shown). Nevertheless, owing to the relatively
small sample size, no definitive conclusion about superiority of
any antibiotic for treatment of MBL-PA HAP can be made.
A limitation of our study was that patients who were dis-
charged within 30 days were not followed-up after their hospi-
talizations, and it is possible that some of them could have died
after hospital discharge within this period. This potential bias
might not have influenced our results, however, since the
lengths of follow-up of patients who have not presented the
outcome did not differ between MBL-PA patients and non-
MBL-PA patients.
Although it was not the scope of this study to investigate the
molecular epidemiology of MBL-PA isolates, horizontal dis-
semination of these isolates has been demonstrated in these
institutions, with SPM-1 being the most common MBL type
[7,19].
Conclusion
MBL production by P. aeruginosa determined a significant
increase in mortality of patients with HAP, particularly of
patients with VAP. A better therapeutic approach is required
to improve outcomes of patients with MBL-PA HAP. Other
investigations to determine the optimal treatment for these
infections are required.Available online http://ccforum.com/content/10/4/R114
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Key messages
•  High mortality rates were observed for patients with 
HAP, particularly VAP, due to P. aeruginosa.
• MBL  production  by  P. aeruginosa significantly 
increases mortality rates of patients with HAP.
•  The effect of MBL production on mortality was probably 
mediated by a more frequent inappropriateness of anti-
microbial therapy for infections due to P. aeruginosa 
producing this enzyme.
•  Presentation with severe sepsis or septic shock, VAP, 
higher comorbidity score, and inappropriateness of 
treatment were independently associated with the 30-
day mortality.
•  The optimal treatment for infections due to MBL-PA 
should be further investigated.